{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T17:01:05Z","timestamp":1753894865928,"version":"3.41.2"},"reference-count":33,"publisher":"Becaris Publishing Limited","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Comp. Eff. Res."],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:p>\n            Acthar\n            <jats:sup>\u00ae<\/jats:sup>\n            Gel (repository corticotropin injection; Mallinckrodt Pharmaceuticals, NJ, USA) is indicated for the treatment of myriad inflammatory disorders and is currently administered manually via a vial and syringe. The administration of Acthar via a single-dose prefilled injector (SelfJect\u2122) is intended to simplify its subcutaneous (SC) delivery. The purpose of this review was to determine whether SelfJect is suitable for use in pediatric patients through a literature assessment of various factors, including skin depth, needle length and gauge, dosage, force required for injection, and potential harms. Infants and young children, who commonly have skin-to-muscle distances less than the minimum depth of SelfJect administration, may have risk of unintentional intramuscular (IM) injection; however, an inadvertent IM injection poses no additional risk to children because of the bioequivalence between SC and IM administration of Acthar. The needle gauge of SelfJect is acceptable for pediatric patients and aligns with the Centers for Disease Control and Prevention recommendations for SC injections. The dosage delivered by SelfJect is only appropriate for children over 2\u00a0years of age. Although adolescents would likely be able to achieve the minimum force required to remove the protective cap and deliver a full dose of Acthar with SelfJect, an adult (18\u00a0years of age and older) should administer SelfJect to pediatric patients. In addition to the commonly reported postmarketing adverse events (AEs) from Acthar administration (e.g., asthenic conditions, fluid retention, insomnia, headache and increased blood glucose), injection site-related AEs common to injection devices may occur with SelfJect use. The risk of needlestick injury from SelfJect is mitigated by a needle guard. In summary, this review of injection device considerations demonstrates that SelfJect is appropriate for use in the pediatric population.\n          <\/jats:p>","DOI":"10.57264\/cer-2024-0132","type":"journal-article","created":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T10:34:27Z","timestamp":1729852467000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical assessment of the potential use of a novel single-dose prefilled injection device for the administration of Acthar Gel in children: a narrative review"],"prefix":"10.57264","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5339-8927","authenticated-orcid":false,"given":"Johanna","family":"Purcell","sequence":"first","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Bridgewater, NJ 08807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2994-5301","authenticated-orcid":false,"given":"Sheila","family":"Elliott","sequence":"additional","affiliation":[{"name":"Mallinckrodt Pharmaceuticals, Bridgewater, NJ 08807, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"36897","reference":[{"key":"e_1_3_7_3_2","unstructured":"Food and Drug Administration. Acthar\u00ae Gel Prescribing information. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/008372s074lbl.pdf (2024)."},{"issue":"8","key":"e_1_3_7_4_2","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/ndt\/gfu069","article-title":"A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar\u00ae Gel) in nephrotic syndrome due to idiopathic membranous nephropathy","volume":"29","author":"Hladunewich MA","year":"2014","unstructured":"Hladunewich MA, Cattran D, Beck LH A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar\u00ae Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Nephrol. Dial. Transplant. 29(8), 1570\u20131577 (2014).","journal-title":"Nephrol. Dial. Transplant."},{"issue":"3","key":"e_1_3_7_5_2","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1542\/peds.97.3.375","article-title":"High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study","volume":"97","author":"Baram TZ","year":"1996","unstructured":"Baram TZ, Mitchell WG, Tournay A, Snead OC, Hanson RA, Horton EJ. High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study. Pediatrics 97(3), 375\u2013379 (1996).","journal-title":"Pediatrics"},{"issue":"12","key":"e_1_3_7_6_2","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1177\/0883073820932710","article-title":"Neuroinflammation in children with infantile spasms: a prospective study before and after treatment with Acthar Gel (repository corticotropin injection)","volume":"35","author":"Chugani HT","year":"2020","unstructured":"Chugani HT, Kumar A. Neuroinflammation in children with infantile spasms: a prospective study before and after treatment with Acthar Gel (repository corticotropin injection). J. Child Neurol. 35(12), 808\u2013812 (2020).","journal-title":"J. Child Neurol."},{"key":"e_1_3_7_7_2","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s12882-016-0241-7","article-title":"Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series","volume":"17","author":"Madan A","year":"2016","unstructured":"Madan A, Mijovic-Das S, Stankovic A, Teehan G, Milward AS, Khastgir A. Acthar gel in the treatment of nephrotic syndrome: a multicenter retrospective case series. BMC Nephrol. 17, 37 (2016).","journal-title":"BMC Nephrol."},{"issue":"1","key":"e_1_3_7_8_2","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1159\/000339287","article-title":"Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial","volume":"36","author":"Bomback AS","year":"2012","unstructured":"Bomback AS, Canetta PA, Beck LH Jr, Ayalon R, Radhakrishnan J, Appel GB. Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Am. J. Nephrol. 36(1), 58\u201367 (2012).","journal-title":"Am. J. Nephrol."},{"key":"e_1_3_7_9_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/IJNRD.S50660","article-title":"Membranous glomerulopathy and treatment with Acthar\u00ae: a case study","volume":"6","author":"Watson MJ","year":"2013","unstructured":"Watson MJ. Membranous glomerulopathy and treatment with Acthar\u00ae: a case study. Int. J. Nephrol. Renovasc. Dis. 6, 229\u2013232 (2013).","journal-title":"Int. J. Nephrol. Renovasc. Dis."},{"key":"e_1_3_7_10_2","unstructured":"Mallinckrodt Pharmaceuticals. Acthar\u00ae Gel Patient support. https:\/\/acthar.com\/Static\/pdf\/PSR_Step_By_Step_Injection_Guide_English.pdf (2021)."},{"key":"e_1_3_7_11_2","doi-asserted-by":"crossref","first-page":"204201882090601","DOI":"10.1177\/2042018820906016","article-title":"Insulin-delivery methods for children and adolescents with type 1 diabetes","volume":"11","author":"Zuberi Z","year":"2020","unstructured":"Zuberi Z, Sauli E, Cun L Insulin-delivery methods for children and adolescents with type 1 diabetes. Ther. Adv. Endocrinol. Metab. 11, 2042018820906016 (2020).","journal-title":"Ther. Adv. Endocrinol. Metab."},{"issue":"1","key":"e_1_3_7_12_2","doi-asserted-by":"crossref","first-page":"e000773","DOI":"10.1136\/bmjdrc-2019-000773","article-title":"Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study","volume":"8","author":"Wysham CH","year":"2020","unstructured":"Wysham CH, Rosenstock J, Vetter ML, Wang H, Hardy E, Iqbal N. Further improvement in glycemic control after switching from exenatide two times per day to exenatide once-weekly autoinjected suspension in patients with type 2 diabetes: 52-week results from the DURATION-NEO-1 study. BMJ Open Diabetes Res. Care. 8(1), e000773 (2020).","journal-title":"BMJ Open Diabetes Res. Care."},{"key":"e_1_3_7_13_2","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.2147\/PPA.S169339","article-title":"Patients' and nurses' preferences for autoinjectors for rheumatoid arthritis: results of a European survey","volume":"12","author":"Tischer B","year":"2018","unstructured":"Tischer B, Mehl A. Patients' and nurses' preferences for autoinjectors for rheumatoid arthritis: results of a European survey. Patient Prefer. Adherence. 12, 1413\u20131424 (2018).","journal-title":"Patient Prefer. Adherence."},{"issue":"1","key":"e_1_3_7_14_2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s40271-017-0276-2","article-title":"Patient evaluation of satisfaction and outcomes with an autoinjector for self-administration of subcutaneous belimumab in patients with systemic lupus erythematosus","volume":"11","author":"Dashiell-Aje E","year":"2018","unstructured":"Dashiell-Aje E, Harding G, Pascoe K, DeVries J, Berry P, Ramachandran S. Patient evaluation of satisfaction and outcomes with an autoinjector for self-administration of subcutaneous belimumab in patients with systemic lupus erythematosus. Patient. 11(1), 119\u2013129 (2018).","journal-title":"Patient."},{"issue":"5","key":"e_1_3_7_15_2","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1002\/cpdd.1073","article-title":"Pharmacokinetics of subcutaneous dupilumab injection with an autoinjector device or prefilled syringe","volume":"11","author":"Cohen YZ","year":"2022","unstructured":"Cohen YZ, Zhang X, Xia B Pharmacokinetics of subcutaneous dupilumab injection with an autoinjector device or prefilled syringe. Clin. Pharmacol. Drug Dev. 11(5), 675\u2013681 (2022).","journal-title":"Clin. Pharmacol. Drug Dev."},{"issue":"7","key":"e_1_3_7_16_2","first-page":"e41601","article-title":"The reliability of auto-injectors in clinical use: a systematic review","volume":"15","author":"Dostal P","year":"2023","unstructured":"Dostal P, Taubel J, Lorch U, Aggarwal V, York T. The reliability of auto-injectors in clinical use: a systematic review. Cureus. 15(7), e41601 (2023).","journal-title":"Cureus."},{"issue":"3","key":"e_1_3_7_17_2","doi-asserted-by":"crossref","first-page":"e20164006","DOI":"10.1542\/peds.2016-4006","article-title":"Epinephrine for first-aid management of anaphylaxis","volume":"139","author":"Sicherer SH","year":"2017","unstructured":"Sicherer SH, Simons FER, Mahr TA Epinephrine for first-aid management of anaphylaxis. Pediatrics 139(3), e20164006 (2017).","journal-title":"Pediatrics"},{"issue":"1","key":"e_1_3_7_18_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1398-9995.2010.02450.x","article-title":"What are the \u2018ideal\u2019 features of an adrenaline (epinephrine) auto-injector in the treatment of anaphylaxis?","volume":"66","author":"Frew AJ","year":"2011","unstructured":"Frew AJ. What are the \u2018ideal\u2019 features of an adrenaline (epinephrine) auto-injector in the treatment of anaphylaxis? Allergy 66(1), 15\u201324 (2011).","journal-title":"Allergy"},{"issue":"29","key":"e_1_3_7_19_2","doi-asserted-by":"crossref","first-page":"3384","DOI":"10.1016\/j.vaccine.2015.04.081","article-title":"Skin thickness in young infants and adolescents: applications for intradermal vaccination","volume":"33","author":"Saitoh A","year":"2015","unstructured":"Saitoh A, Aizawa Y, Sato I, Hirano H, Sakai T, Mori M. Skin thickness in young infants and adolescents: applications for intradermal vaccination. Vaccine 33(29), 3384\u20133391 (2015).","journal-title":"Vaccine"},{"issue":"4","key":"e_1_3_7_20_2","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.vaccine.2019.11.002","article-title":"Skin thickness measurements for optimal intradermal injections in children","volume":"38","author":"Van Mulder TJS","year":"2020","unstructured":"Van Mulder TJS, Van Nuffel D, Demolder M Skin thickness measurements for optimal intradermal injections in children. Vaccine 38(4), 763\u2013768 (2020).","journal-title":"Vaccine"},{"issue":"7","key":"e_1_3_7_21_2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1399-5448.2012.00865.x","article-title":"Skin and subcutaneous thickness at injecting sites in children with diabetes: ultrasound findings and recommendations for giving injection","volume":"13","author":"Lo Presti D","year":"2012","unstructured":"Lo Presti D, Ingegnosi C, Strauss K. Skin and subcutaneous thickness at injecting sites in children with diabetes: ultrasound findings and recommendations for giving injection. Pediatr. Diabetes. 13(7), 525\u2013533 (2012).","journal-title":"Pediatr. Diabetes."},{"issue":"7","key":"e_1_3_7_22_2","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1136\/adc.66.7.879","article-title":"Subcutaneous or intramuscular insulin injections","volume":"66","author":"Smith CP","year":"1991","unstructured":"Smith CP, Sargent MA, Wilson BP, Price DA. Subcutaneous or intramuscular insulin injections. Arch. Dis. Child. 66(7), 879\u2013882 (1991).","journal-title":"Arch. Dis. Child."},{"issue":"12","key":"e_1_3_7_23_2","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.2337\/diacare.19.12.1434","article-title":"Subcutaneous or intramuscular injections of insulin in children. Are we injecting where we think we are?","volume":"19","author":"Polak M","year":"1996","unstructured":"Polak M, Beregszaszi M, Belarbi N Subcutaneous or intramuscular injections of insulin in children. Are we injecting where we think we are? Diabetes Care 19(12), 1434\u20131436 (1996).","journal-title":"Diabetes Care"},{"issue":"10","key":"e_1_3_7_24_2","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.2337\/diacare.22.10.1621","article-title":"Short needles (8 mm) reduce the risk of intramuscular injections in children with type 1 diabetes","volume":"22","author":"Tubiana-Rufi N","year":"1999","unstructured":"Tubiana-Rufi N, Belarbi N, Du Pasquier-Fediaevsky L Short needles (8 mm) reduce the risk of intramuscular injections in children with type 1 diabetes. Diabetes Care 22(10), 1621\u20131625 (1999).","journal-title":"Diabetes Care"},{"issue":"9","key":"e_1_3_7_25_2","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.2337\/dc08-0977","article-title":"A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults","volume":"31","author":"Birkebaek NH","year":"2008","unstructured":"Birkebaek NH, Solvig J, Hansen B, Jorgensen C, Smedegaard J, Christiansen JS. A 4-mm needle reduces the risk of intramuscular injections without increasing backflow to skin surface in lean diabetic children and adults. Diabetes Care 31(9), e65 (2008).","journal-title":"Diabetes Care"},{"issue":"12","key":"e_1_3_7_26_2","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1111\/j.1464-5491.2007.02272.x","article-title":"An angled insertion technique using 6-mm needles markedly reduces the risk of intramuscular injections in children and adolescents","volume":"24","author":"Hofman PL","year":"2007","unstructured":"Hofman PL, Lawton SA, Peart JM An angled insertion technique using 6-mm needles markedly reduces the risk of intramuscular injections in children and adolescents. Diabet. Med. 24(12), 1400\u20131405 (2007).","journal-title":"Diabet. Med."},{"issue":"9","key":"e_1_3_7_27_2","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.2337\/dc10-0871","article-title":"Defining the ideal injection techniques when using 5-mm needles in children and adults","volume":"33","author":"Hofman PL","year":"2010","unstructured":"Hofman PL, Derraik JG, Pinto TE Defining the ideal injection techniques when using 5-mm needles in children and adults. Diabetes Care 33(9), 1940\u20131944 (2010).","journal-title":"Diabetes Care"},{"issue":"4","key":"e_1_3_7_28_2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.biopha.2008.08.022","article-title":"Bio-equivalence of IM and SQ H.P. Acthar Gel","volume":"63","author":"Brod SA","year":"2009","unstructured":"Brod SA, Morales MM. Bio-equivalence of IM and SQ H.P. Acthar Gel. Biomed. Pharmacother. 63(4), 251\u2013253 (2009).","journal-title":"Biomed. Pharmacother."},{"key":"e_1_3_7_29_2","unstructured":"Kroger A Bahta L Long S Sanchez P. Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. General best practice guidelines for immunization. https:\/\/www.cdc.gov\/vaccines\/hcp\/acip-recs\/general-recs\/index.html (2023)."},{"issue":"2","key":"e_1_3_7_30_2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/17425247.2020.1704730","article-title":"Hold the device against the skin: the impact of injection duration on user's force for handheld autoinjectors","volume":"17","author":"Schneider A","year":"2020","unstructured":"Schneider A, Mueller P, Jordi C Hold the device against the skin: the impact of injection duration on user's force for handheld autoinjectors. Expert Opin. Drug Deliv. 17(2), 225\u2013236 (2020).","journal-title":"Expert Opin. Drug Deliv."},{"issue":"2","key":"e_1_3_7_31_2","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1682\/JRRD.2004.02.0215","article-title":"Identification of key pinch forces required to complete functional tasks","volume":"41","author":"Smaby N","year":"2004","unstructured":"Smaby N, Johanson ME, Baker B, Kenney DE, Murray WM, Hentz VR. Identification of key pinch forces required to complete functional tasks. J. Rehabil. Res. Dev. 41(2), 215\u2013224 (2004).","journal-title":"J. Rehabil. Res. Dev."},{"key":"e_1_3_7_32_2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2147\/PPA.S298725","article-title":"User-centric approach to specifying technical attributes of drug delivery devices: empirical study of autoinjector-cap removal forces","volume":"15","author":"Schneider A","year":"2021","unstructured":"Schneider A, Richard P, Mueller P, Jordi C, Yovanoff M, Lange J. User-centric approach to specifying technical attributes of drug delivery devices: empirical study of autoinjector-cap removal forces. Patient Prefer. Adherence. 15, 159\u2013168 (2021).","journal-title":"Patient Prefer. Adherence."},{"key":"e_1_3_7_33_2","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.2147\/PPA.S170636","article-title":"Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies","volume":"12","author":"Stauffer VL","year":"2018","unstructured":"Stauffer VL, Sides R, Lanteri-Minet M Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. Patient Prefer. Adherence. 12, 1785\u20131795 (2018).","journal-title":"Patient Prefer. Adherence."},{"key":"e_1_3_7_34_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/PPA.S70834","article-title":"Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective","volume":"9","author":"Bolge SC","year":"2015","unstructured":"Bolge SC, Goren A, Tandon N. Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective. Patient Prefer. Adherence. 9, 121\u2013131 (2015).","journal-title":"Patient Prefer. Adherence."},{"issue":"8","key":"e_1_3_7_35_2","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1080\/17425247.2024.2390553","article-title":"Formative and validation human factors studies of a new disposable prefilled injection device for subcutaneous delivery of acthar gel (repository corticotropin injection)","volume":"21","author":"Linnane A","year":"2024","unstructured":"Linnane A, Lau M, Miranda P, Elliott S. Formative and validation human factors studies of a new disposable prefilled injection device for subcutaneous delivery of acthar gel (repository corticotropin injection). Expert Opin. Drug Deliv. 21(8), 1263\u20131278 (2024).","journal-title":"Expert Opin. Drug Deliv."}],"container-title":["Journal of Comparative Effectiveness Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/becarispublishing.com\/doi\/pdf\/10.57264\/cer-2024-0132","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,28]],"date-time":"2024-11-28T11:58:14Z","timestamp":1732795094000},"score":1,"resource":{"primary":{"URL":"https:\/\/becarispublishing.com\/doi\/10.57264\/cer-2024-0132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":33,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.57264\/cer-2024-0132"],"URL":"https:\/\/doi.org\/10.57264\/cer-2024-0132","relation":{},"ISSN":["2042-6305","2042-6313"],"issn-type":[{"type":"print","value":"2042-6305"},{"type":"electronic","value":"2042-6313"}],"subject":[],"published":{"date-parts":[[2024,12]]},"article-number":"e240132"}}